本文選題：升降散　切入點：早期糖尿病腎病　出處：《華北理工大學》2017年碩士論文

【摘要】：目的觀察升降散加減方聯(lián)合厄貝沙坦對早期糖尿病腎病患者的瘦素、尿微量白蛋白、胱抑素C、β2微球蛋白、血脂、同型半胱氨酸、超敏C-反應蛋白等指標的影響,從而證明聯(lián)合治療通過對早期糖尿病腎病患者血脂水平、瘦素等的調節(jié),對腎功能有一定的改善,為中西醫(yī)聯(lián)合治療早期糖尿病腎病提供數(shù)據(jù)及理論支持。方法將符合標準的2型糖尿病腎病患者按照隨機、開放的原則平均分成兩組,每組各31人。其中對照組予飲食干預、健康教育、體育鍛煉,胰島素控制血糖等常規(guī)治療,并予厄貝沙坦150mg,每天1次。治療組在此基礎上予升降散加減方,每日一劑,早晚各一次,每次150m L。待療程8周后,觀察并比較治療前后兩組患者的臨床癥狀體征及各項實驗室指標的變化。結果經治療后,兩組觀察對象總有效率分別為:治療組90.3%,對照組74.2%,與對照組相比治療組總有效率明顯較高(P0.05);治療后,治療組Cys C、UAER、TG、HDL、Leptin與對照組相比差異顯著(P0.05),差值具有統(tǒng)計學意義(P0.05)。結論升降散加減方與厄貝沙坦聯(lián)合使用對早期糖尿病腎病患者的高血脂狀態(tài)有所改善,并可調節(jié)瘦素水平,還可減少尿蛋白的排泄,進而明顯改善腎功能,且效果優(yōu)于單純厄貝沙坦的使用,值得臨床進一步研究及應用。
[Abstract]:Objective to observe the effects of Shengshang decoction and irbesartan on leptin, urinary microalbumin, cystatin C, 尾 2 microglobulin, blood lipid, homocysteine and hypersensitive C-reactive protein in patients with early diabetic nephropathy. It is proved that combined therapy can improve renal function by regulating blood lipid level and leptin levels in early diabetic nephropathy patients. Methods the patients with type 2 diabetic nephropathy were divided into two groups according to the principle of randomness and openness, 31 people in each group. The control group was treated with diet intervention. Health education, physical exercise, insulin control of blood glucose and other routine treatment, and irbesartan 150 mg, once a day. Observe and compare the changes of clinical symptoms and signs and laboratory indexes before and after treatment. The total effective rates of the two groups were 90.3 in the treatment group and 74.2in the control group. The total effective rate of the treatment group was significantly higher than that of the control group (P 0.05). The difference between the treatment group and the control group was significant (P 0.05), and the difference was statistically significant (P 0.05). Conclusion the combination of Shengsheng Powder and Irbesartan can improve the hyperlipidemia of the patients with early diabetic nephropathy and regulate the level of leptin. It can also reduce urinary protein excretion and improve renal function obviously, and the effect is better than that of irbesartan alone, which is worthy of further clinical study and application.
【學位授予單位】：華北理工大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R587.2;R692.9

【參考文獻】

相關期刊論文 前10條

1 向敏;;中西醫(yī)結合治療糖尿病研究進展[J];世界最新醫(yī)學信息文摘;2016年68期

2 朱蓓;宋衛(wèi)國;彭t，

本文編號：1690786